Pfizer says its Phase 3 clinical trial confirmed COVID-19 vaccine protection lasts at least six months after the second dose and covers emerging variants.
Originally, the company could only guarantee 90 days of protection for vaccinated patients, making six months of protection the best estimate offered to date, according to a Pfizer/BioNTech readout.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.
